P. Johnson

Clinical trials of antibody therapy.

M. Glennie, P. Johnson, M J Glennie, 2000, Immunology today.

Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial

M. Glennie, P. Johnson, F. Chowdhury, 2013, Cancer Immunology Research.

Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum.

M. Glennie, P. Johnson, F. Chowdhury, 2010, Journal of immunological methods.

T cell‐dependent suppression of antibody production. I. Characteristics of suppressor T cells following tolerance induction

R. Callard, J. Gamble, J. Miller, 1978, European journal of immunology.

T Cell‐Dependent Suppression of an Anti‐Hapten Antibody Response

A Basten, J. Miller, P. Johnson, 1975, Transplantation reviews.

Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules.

F. Finkelman, P. Johnson, J. Inman, 1994, Vaccine.

Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1

R. Young, B. Walker, R. Johnson, 1994, The Journal of experimental medicine.

Cancer immunotherapy with a chimeric anti-CD40 monoclonal antibody: Evidence of preclinical efficacy.

M. Glennie, P. Johnson, T. Geldart, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.